Improve sleep in Parkinson patients
- Trial ID
- NCT05962489
- Official Title
- Sleep-specific DBS Therapy in Parkinson's Disease
- Goal
- Improve sleep in Parkinson patients
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Minnesota
- Study Type
- INTERVENTIONAL
- Enrollment
- 64 participants
- Conditions
- Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Dystonia
- Interventions
- Clinically optimized deep brain stimulation
Plain-Language Summary
The goal is to improve sleep in people with Parkinson's by using deep brain stimulation that is specifically tuned to sleep states, so stimulation can better regulate the brain circuits that disrupt normal sleep. The approach implants directional DBS leads bilaterally in either the globus pallidus interna or subthalamic nucleus as part of routine surgical care at the University of Minnesota, uses 7T imaging and sleep-focused programming and recordings, and adjusts electrical pulses to modulate abnormal neural activity during sleep. Participants must be adults 21 or older with idiopathic Parkinson's who are planning or have had bilateral GPi or STN DBS with directional leads at UMN and can undergo the required imaging, while people with dementia, other major neurological disorders, pregnancy, recent unsafe radiation exposure, or certain post-op complications are excluded.
Locations
- University Of Minnesota, Minneapolis, Minnesota, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Clinically optimized deep brain stimulation. The goal is to improve sleep in people with Parkinson's by using deep brain stimulation that is specifically tuned to sleep states, so stimulation can better regulate the brain circuits that disrupt normal sleep. The approach implants directional DBS leads bilaterally in either the globus pallidus interna or subthalamic nucleus as part of routine surgical care at the University of Minnesota, uses 7T imaging and sleep-focused programming and recordings, and adjusts electrical pulses to modulate abnormal neural activity during sleep. Participants must be adults 21 or older with idiopathic Parkinson's who are planning or have had bilateral GPi or STN DBS with directional leads at UMN and can undergo the required imaging, while people with dementia, other major neurological disorders, pregnancy, recent unsafe radiation exposure, or certain post-op complications are excluded.
- Who can participate?
- Participants must be at least 21 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years and 1 month.